Introduction
Tuberculosis is an airborne disease caused by microorganisms of the Mycobacterium tuberculosis complex and generally affects the lungs, although almost any tissue of the body can be infected (Pai et al., 2016) . The mortality rate from tuberculosis declined in industrialized countries between 1940 and the 1980s owing to improvements in socioeconomic conditions and the introduction of several antimicrobial agents such as streptomycin, isoniazid, rifampicin, pyrazinamide and paraaminosalicylic acid (PAS) (Lienhardt, 2001; Lienhardt et al., 2012) . However, successful treatment of tuberculosis could not be easily implemented in developing countries because of their deteriorated public health systems and often also economic crises (Berman, 1995) . Consequently, this disease remains a problem in these countries, mainly in Africa and Asia, where approximately eight million new cases were ISSN 2059-7983 # 2019 International Union of Crystallography estimated to have occurred between 1989 and 1990 (Lienhardt et al., 2012) . In 2016, 1.7 million tuberculosis-related deaths were reported, including those of patients infected with HIV (Lienhardt et al., 2018) , and tuberculosis was the leading cause of death from a single agent among all infectious diseases (World Health Organization, 2017) . Although several signs of progress have recently been achieved, including the introduction of at least two new drugs, bedaquiline and pretomanid, to the market, tuberculosis still remains a serious public health problem and research into it is considered to be underfunded (Lienhardt et al., 2018) . In addition, resistance to the most commonly used drugs has spread worldwide and has made the treatment of this disease even more complicated, requiring long-term therapy using toxic medicines, which has further contributed to the emergence of resistant strains (Pai et al., 2016) . Thus, the discovery of new drugs or the repurposing of existent ones is urgently needed.
Although the folate pathway is essential for bacteria, including M. tuberculosis, there is no drug that targets this pathway in the treatment regimen for tuberculosis. The folate pathway is constituted by six enzymes that convert GTP into tetrahydrofolate, an essential vitamin (B 9 ), which is used as a coenzyme in several key processes of metabolism, including DNA replication and the biosynthesis of several amino acids and pantothenate (Dias et al., 2018; Bermingham & Derrick, 2002) . Most bacteria, fungi, plants and protozoa are not able to take up folate from the medium and hence these organisms have to produce tetrahydrofolate de novo (Hanson & Gregory, 2011) . Thus, the enzymes of this pathway are potential targets in drug-discovery campaigns against pathogenic microorganisms (Woods, 1940; Hitchings & Elion, 1948 ; Bermingham & Derrick, 2002; Schneider et al., 2003; Dias et al., 2018) . Indeed, several drugs that inhibit the folate pathway are used to treat infectious diseases, including sulfa drugs, which inhibit dihydropteroate synthase (DHPS; Yun et al., 2012) , trimethoprim (Darrell et al., 1968 ) and pyrimethamine (Wilson & Edeson, 1953) , which are effective against bacterial urinary infections and malaria, respectively (Gangjee et al., 2007; Hawser et al., 2006) . In addition, PAS has also been suggested to target this pathway after being metabolized by DHPS, inhibiting the downstream dihydrofolate synthase (DHFS) or dihydrofolate reductase (DHFR) (Chakraborty et al., 2013) . Hence, DHPS and DHFR are the most explored enzymes of this pathway for the treatment of infections, and combinations of sulfamethoxazole, trimethoprim and other drugs are still largely used (Kester et al., 2012; Minato et al., 2018) .
However, trimethoprim and pyrimethamine do not show potent activity against M. tuberculosis DHFR (MtDHFR; Huang et al., 2012) and a number of studies have proposed new compounds that targeted this enzyme, although most of them did not show satisfactory activity in vivo (Mugumbate et al., 2015; Kumar et al., 2012; Gerum et al., 2002; Hong et al., 2015) . We have proposed that MtDHFR might have a low affinity for most classical antifolate inhibitors since this enzyme can adopt two conformational states because of increased flexibility of the active site (Dias et al., 2014) . The high mobility of NADPH might be caused by a steric clash between key residues in the active site, including Tyr100, and the nicotinamide moiety of NADPH. However, upon substrate binding, the nicotinamide moiety can engage in the active site and promote catalysis. This movement of the nicotinamide moiety of NADPH in and out of the active site allows the enzyme to adopt two distinct conformations, an open and a closed state, which was also described for other DHFRs, including human DHFR (Bhabha et al., 2013) and trimethoprim-resistant DHFR from Staphylococcus aureus (Frey et al., 2009) . The effect of this movement could be associated with a reduced affinity for antifolates since their interaction with DHFR involves interactions of the nicotinamide moiety with the pyrimidine ring of the inhibitors (Dias et al., 2014; Frey et al., 2009 ). In addition, we have also previously described the binding modes of pyrimethamine and cycloguanil, the activated form of the prodrug proguanil, in the active site of the open state of MtDHFR (Dias et al., 2014 ), but we were not able at the time to provide structural information about these compounds in the closed state of MtDHFR. The binding modes of other classical antifolates, with the exception of trimethoprim, have so far not been studied for MtDHFR, including those of diaverdine and pemetrexed, two other dihydrofolate inhibitors.
In order to understand the binding modes of classical antifolates other than trimethoprim in the closed conformation of MtDHFR, we have performed a structural study of MtDHFR in the presence of four different antifolates: pyrimethamine (PYR), cycloguanil (CYC), diaverdine (DIA) and pemetrexed (PMX) (Fig. 1 ). In addition, we have also obtained the structure of the holoenzyme in complex with dihydrofolate (DHF) and estimated the affinity, through K d determination, for DIA and methotrexate (MTX), which have so far not been reported for MtDHFR. The structures of MtDHFR in complex with the different ligands reported here provide insights into the mechanism of this enzyme and into the modes of antifolate binding to MtDHFR.
Materials and methods

Cloning, expression and purification of MtDHFR
The cloning and expression of the M. tuberculosis dhfA gene and the purification of MtDHFR were carried out as described in Dias et al. (2014) and Argyrou et al. (2006) with slight modifications. Briefly, the dhfA gene was inserted into pET-28a(+) vector and Escherichia coli BL21(DE3) competent cells were transformed using this plasmid for protein expression. The cells were grown at a temperature of 37 C until the OD 600 reached 0.6; they were then induced using 0.2 mM IPTG and the culture was maintained on a shaker for a further 20 h at 18 C. Afterwards, the cells were harvested by centrifugation, resuspended in 20 mM potassium phosphate, 50 mM KCl pH 7.0 and disrupted using a sonicator (Branson Sonifier) with the addition of 1 mM PMSF, 0.2 mg ml À1 lysozyme and 1 mM DNAse (Sigma-Aldrich). The soluble and insoluble fractions were separated by centrifugation at 33 250g research papers at 4 C for 1 h and the protein was purified in two steps from the supernatant using a nickel-affinity IMAC column (GE Healthcare) and a Superdex 16/600 200 pg column (GE Healthcare). The protein was eluted using 20 mM potassium phosphate, 50 mM KCl pH 7.0 and was concentrated to 10 mg ml À1 .
Isothermal titration calorimetry (ITC)
ITC experiments were performed using a VP-ITC isothermal calorimeter (MicroCal) at 26 C. To measure the thermodynamic parameters for DIA interaction, about 1.8 ml of 40 mM MtDHFR in buffer consisting of 20 mM potassium phosphate, 50 mM KCl pH 7.0, 1 mM NADPH, 5% DMSO in the calorimeter cell was titrated against 0.7 mM DIA in the syringe in exactly the same protein buffer. Titration parameters were established as described in Dias et al. (2014) . Heats of dilution were obtained from titrations of ligand against the buffer and were then subtracted from the raw data. These data were described using a 'one-set-of-sites' binding model in Origin 7.0 (MicroCal). In contrast, to measure the thermodynamic parameters for MTX interaction, we performed a competitive titration experiment (Velazquez-Campoy & Freire, 2006) . We had previously performed an ITC experiment to obtain the thermodynamic parameters for CYC, which were in close agreement with those reported previously (Dias et al., 2014) , and we subsequently titrated about 1.8 ml of 40 mM MtDHFR in the cell in the same buffer described above in the presence of 1 mM NADPH and 0.7 mM CYC against 0.4 mM MTX in the syringe. The data were treated as a competitive binding model in Origin 7.0 (MicroCal) using the parameters obtained for CYC. The thermodynamic equations ÁG = ÀRTlnK a and ÁG = ÁH À TÁS were used to calculate the Gibbs free energy and binding entropy.
Crystallization, X-ray data collection and structure determination
MtDHFR at a concentration of 10 mg ml À1 in 20 mM potassium phosphate, 50 mM KCl pH 7.0 incubated in the presence of 5 mM NADPH was screened against approximately 500 conditions using screening kits from Jena Bioscience and Hampton Research. Bipyramidal crystals appeared after 2-30 days in a condition consisting of 1.8 M ammonium sulfate, 100 mM MES-Na [2-(N-morpholino)ethanesulfonic acid sodium], 10 mM cobalt chloride pH 6.5. Once we had established the crystallization conditions for MtDHFR-NADPH crystals, co-crystallization experiments using the five different ligands were carried out: pyrimethamine (PYR), cycloguanil (CYC), diaverdine (DIA), pemetrexed (PMX) and dihydrofolate (DHF). MtDHFR with 5 mM NADPH was incubated for 30 min on ice in the presence of 10-20 mM PYR, CYC, DIA, PMX or DHF, and the crystallization experiments were performed as for the MtDHFR-NADPH complex. The chemical structures of the molecules used in this study are shown in Fig. 1 as well as the structures of MTX and TMP, which were used for comparison purposes.
For data collection, crystals of MtDHFR in complex with the different ligands were cryoprotected in a solution consisting of 25% glycerol or ethylene glycol and 75% of the well solution and were then flash-cooled in liquid nitrogen. Data were acquired at Laborató rio Nacional de Luz Síncrotron (LNLS), Campinas, Brazil. For each data set, about 1800 images were collected with an oscillation angle of 0.2 and an X-ray exposure time of 1 s with 100% transmission. The data were acquired using a PILATUS 2M image-plate detector.
The data sets were processed using XDS (Kabsch, 2010) and were scaled using AIMLESS from the CCP4 suite (Winn et al., 2011) . The structures of MtDHFR-NADPH in complex with the different ligands were solved by molecular replacement with Phaser (McCoy, 2007) from the CCP4 suite using the coordinates of PDB entry 1dg8 (Li et al., 2000) as a search model for the MtDHFR-NADPH-TMP complex and the coordinates of the MtDHFR-NADPH-DHF complex as the search model for the other complexes. The structures of the MtDHFR-NADPH complexes were refined using phenix.refine (Afonine et al., 2012) from the PHENIX package (Adams et al., 2011) using the TLS, NCS and simulating-annealing options. Visual inspections and real-space refinement were carried out using Coot (Emsley et al., 2010) . All figures were prepared using PyMOL (v.1.8; Schrö dinger).
Results and discussion
Crystals of MtDHFR in ternary complexes with NADPH and five different ligands were obtained using a new crystallization condition that has not previously been reported in the literature and showed reproducibility for all of the protein-ligand complexes described here. The crystals of the ternary complexes of MtDHFR with different ligands diffracted to resolutions of 1.8-1.5 Å . The crystals belonged to space group P2 1 2 1 2 1 and contained two molecules in the asymmetric unit. The X-ray data-collection, refinement and stereochemical quality statistics are shown in Table 1 .
The structure of MtDHFR has a Rossmannoid fold (Rossmann et al., 1974) constituted of a -sheet flanked by four -helices, as previously reported by Li et al. (2000) (Fig. 2 ). The enzyme is described to have two domains, the adenosinebinding domain and the loop domain, and the active site is located in a groove between them (Dias et al., 2014) . Most of the NADPH is located in the adenosine-binding domain that extends to the active-site groove, where the nicotinamide moiety is located, allowing it to be juxtapositioned with the pterin ring of the dihydrofolate during catalysis (Fig. 2) . All crystal structures of MtDHFR obtained in this work are in the closed-state conformation, indicating that the nicotinamide moiety of NADPH is engaged on the active site (Dias et al., 2014) . In addition, clear OMIT map electron density is observed for all antifolates and dihydrofolate (Fig. 3) . Furthermore, the overall structure of the protomers superposed very well with the previously reported closed-state conformation of MtDHFR ( Supplementary Table S1 ; Dias et al., 2014; Li et al., 2000) and the adenosine domain is displaced by about 4 Å in comparison to the open-state conformation (Dias et al., 2014 ; Supplementary Fig. S1 ), giving an r.m.s.d. of about 1.0 Å between the two states. On the other hand, the two protomers in the asymmetric unit also superpose with an r.m.s.d. of about 0.4 Å . However, interestingly, an ion from the crystallization condition, probably cobalt, is coordinated by residues of both protomers in the asymmetric unit. Two cobalt ions are coordinated by His38 from one protomer, His157 from the adjacent protomer and a further four water molecules, producing a pseudo-dimeric form of MtDHFR with a twofold pseudosymmetry axis ( Supplementary Fig. S2 ). Analysis of possible dimer formation using PISA (Krissinel & Henrick, 2007) and size-exclusion chromatography using two different buffers indicated no dimeric oligomerization of MtDHFR.
3.1. Comparison of the structures of MtDHFR in ternary complexes with NADPH and DHF, MTX or PMX MTX and PMX are two antifolates that are very similar to DHF, and consequently would be expected to have a similar effect on the conformation of MtDHFR. MTX has a diaminopterin group which is connected to the benzyl group through a methyl-methylamino linker, while DHF has a 2amino-4-oxopterin moiety linked to the benzyl group through a methylamino linker. PMX, which is a classical antifolate derivative of MTX, instead has a pyrrolopyrimidine ring and an ethylbenzoylamino moiety ( Fig. 1) and has been used in cancer therapy since it also targets both human DHFR and human thymidylate synthase (Jackman et al., 2008; Kompis et al., 2005) . Consequently, this compound is designated to be a multitarget antifolate (Gangjee et al., 2008) . However, there are only a few structural studies of the interaction of PMX and DHFR, although the structure of the complex of the holoenzyme with pemetrexed has been reported for Babesia bovis DHFR (Begley et al., 2011) The overall structure of the closed conformation of MtDHFR in complex with dihydrofolate. The co-enzyme NADPH is shown in green and the substrate dihydrofolate (DHF), which binds between the adenosine domain and the loop domain, is shown in yellow. Sacchettini, unpublished work), indicating that this compound targets enzymes in both parasites and mycobacteria, as expected; it could provide an interesting scaffold for the synthesis of specific antifolates targeting the bacterial folate pathway.
Although the structure of MtDHFR in a ternary complex with NADPH and MTX was obtained by Li et al. (2000) , a structure of the ternary complex with DHF has not so far been reported. In order to understand the binding mode of the substrate in the active site of MtDHFR, we solved this structure at a resolution of 1.7 Å . Although MTX and DHF are very similar, superposition of the structures of MtDHFR in ternary complexes with DHF and MTX reveals that the substrate and analog bind in different modes in the active site of MtDHFR [ Fig. 4(a) and Supplementary Fig. S3 ], similar to as observed for E. coli DHFR (EcDHFR; Sawaya & Kraut, 1997) . The pteridine rings of these two compounds are flipped by about 180 as the 4-oxopteridine group of DHF is oriented in the opposite direction to the 2,4-diamino group of the pteridine group of MTX; consequently, hydrogen bonds to the backbone O atoms of Ile5 and Ile94 are not possible [ Fig. 4(a) ]. On the other hand, the O atom of the 2-amino-4-oxopteridine ring of DHF interacts with Trp22, Gln28, the side chain of Asp27 and the backbone of Leu24 through two water molecules. However, the inverted orientation of the pteridine ring of MTX increases the distance to the nicotinamide moiety of NADPH since C4 of the cofactor and C6 of the substrate analog are at a distance of about 4.6 Å , in contrast to 3.9 Å for the cofactor and substrate [ Fig. 3(b) ]. Superposition of the MtDHFR-NADPH-DHF and MtDHFR-NADPH-MTX complexes indicates that the distance of C6 from the substrate and inhibitor is about 1.1 Å , which also causes a shift in the position of the p-aminobenzoylglutamate moiety of the substrate in comparison to the inhibitor. In addition, owing to the rotation of the pteridine ring of MTX in relation to DHF, the benzoyl ring of the p-aminobenzoylglutamate moiety is translated about 0.7 Å towards the active site, although the position of the glutamate moiety does not change significantly [ Fig. 4(b) ].
In addition, in order to reveal whether different rings and linkers of the p-aminobenzoylglutamate moiety could cause conformational changes or lead to different binding modes, we determined the structure of the MtDHFR-NADPH-PMX ternary complex. As expected, PMX binds in the same binding pocket as DHF (Fig. 3) , despite key binding-mode differences [ Fig. 4(c) ]. The glutamate moiety of PMX binds in the same position as DHF and makes an ionic interaction with Arg60, while this ethylbenzoylamino moiety is rotated by about 47 in comparison to the p-aminobenzoic acid moiety of DHF [ Fig. 4(c) ]. This rotation also influences the position of the ethyl linker and consequently the binding mode of the pyrrolopyrimidine ring. Although the oxopyrimidine ring of PMX adopts a similar orientation to DHF [Fig. 4(c) ], the pyrrolopyrimidine moiety superposes very well with the diaminopterin moiety of MTX [ Fig. 4(d) ]. In contrast, owing to the rotation of the ethylbenzoyl moiety of PMX and the displacement of the pyrrolopyrimidine ring, the side chain of Gln28 adopts a different rotamer and interacts with the 4-oxo group of this moiety of PMX [ Fig. 4(c) ]. In addition, it is possible to observe a displacement of about 1.2 Å in the loop between residues 49 and 55 in the structure of MtDHFR-NADPH-PMX, probably adjusting the distended position of the ethylbenzoylamino moiety, which could be sterically impeded by the side chain of Leu50 [ Fig. 4(e) ]. Interestingly, superposition of the MtDHFR-NADPH-PMX complex with the structure of dihydrofolate reductase-thymidylate synthase from B. bovis in complex with NADPH and PMX (Begley et al., 2011) shows that the ethylbenzoylamino moiety has rotated about 122 and it is in a perpendicular position in relation to the position of PMX in the MtDHFR-NADPH-PMX complex. This rotation could be caused by the side chain of Ile73 (Leu50 in MtDHFR) that protrudes into the p-aminobenzoylglutamate binding-site cavity and restricts the position of the benzoyl group [ Fig. 4( f) ]. Moreover, the binding pocket for the p-aminobenzoic acid moiety in these two DHFRs differs considerably in the position of the aromatic amino-acid residues, which might influence the orientation of this moiety in these enzymes. On the other hand, the positions of the pyrrolopyrimidine rings of the two complexes superpose very well and they make essentially the same hydrogen-bond interactions with the active-site residues [ Fig. 4(f) ].
Binding mode of DIA to MtDHFR-NADPH and comparison with TMP
In contrast to MTX and PMX, TMP and DIA are shorter compounds with a flexible linker between the two rings that include a diaminopyrimidine group and a trimethoxyphenyl or dimethoxyphenyl group, respectively. Consequently, DIA is a very similar compound to TMP and the unique difference is the absence of the methoxy group at the C5 position of the phenyl ring (Fig. 1) . In order to investigate the effect of the lack of a methoxy group on the phenylpyrimidine in DIA on the ligand-binding mode and protein conformation, we solved the structure of the MtDHFR-NADPH-DIA ternary complex and compared it with the structure of the MtDHFR-NADPH-TMP complex solved previously (Li et al., 2000) .
Superposition of MtDHFR-NADPH-TMP and MtDHFR-NADH-DIA gave an r.m.s.d. of 0.66 Å and also indicated that both compounds bind in the same pocket of MtDHFR (as expected). However, the absence of the C5 methoxy group on the phenyl ring of DIA might have a considerable effect on its binding mode. Interestingly, superposition of the two protomers of the asymmetric unit of the MtDHFR-NADPH-DIA crystal indicates that DIA adopts a different binding mode in the two protein chains. Thus, the absence of the C5 methoxy group may increase the flexibility of DIA in the active site owing to fewer restrictions [Figs. 5(a) and 5(b)]. The binding mode of DIA in one of the protomers (A) is very similar to that in the MtDHFR-NADPH-TMP complex (Li et al., 2000) and all of the hydrogen interactions are preserved [ Fig. 5(b) ]. On the other hand, in the other protomer (B), the DIA dimethoxyphenyl and TMP trimethoxyphenyl rings have different rotation angles, although the 2,4-pyrimidinediamine groups of DIA and TMP bind in the same mode [ Fig. 5(c) ]. The C5 methoxy group of TMP interacts through van der Waals contacts with the side chain of Ser49 and with a hydroxyl group of the ribose moiety of NADPH. The absence of this group in DIA might cause a rotation of the plane of the dimethoxyphenyl ring by about 25 that increases its distance to Ser49 and NADPH by about 1.0 and 0.6 Å , respectively. In addition, since we did not use glycerol for protein purification and in this crystallization experiment, we could observe further differences in our structure in comparison to the structure solved by Li et al. (2000) . A glycerol molecule interacts with TMP through hydrogen-bond and van der Waals contacts in the MtDHFR-NADPH-TMP ternary complex solved by Li et al. (2000) . In contrast, in the MtDHFR-NADPH-DIA ternary complex it is possible to observe interactions of the O atoms of the C2 and C3 methoxy groups with water molecules. The superposition of MtDHFR-NADPH-DIA (protomer A) and MtDHFR-NADPH-TMP also indicates a conformational change in the protein chain, which is probably caused by a torsion in the main chain of Ser49, allowing opening of the active site in the MtDHFR- NADPH-DIA complex since the residues between Leu50 and Val54 have a displacement of about 1.0 Å . Owing to the rotation of the plane of the dimethoxyphenyl group of DIA, the residues Ile20-Gln28 are also displaced, causing a change in the cavity volume of MtDHFR [ Fig. 5(c) ]. The most prominent changes are observed in the hydrogen-bond profile of Asp27 to the 2,4-pyrimidinediamine of these molecules and also in the rotation of the side chain of Gln28, which allows its interaction with the 2-methoxy group of DIA through a hydrogen bond [ Fig. 5(d) ].
Comparison of MtDHFR in complex with PYR and CYC in different conformation states
In contrast to the antifolates analysed here so far, PYR and CYC are more rigid molecules and they can only rotate around their own axes. PYR and CYC contain a diaminopyrimidine and a triazine ring, respectively, which are linked through C5 and N1 (Fig. 1) to a chlorophenyl ring. In previous work, we determined the structures of the MtDHFR-NADPH-PYR and MtDHFR-NADPH-CYC complexes in an open-state conformation. In these structures, we observed that the triazine and the dipyrimidine groups of CYC and PYR, respectively, bind in essentially the same position as the dipyrimidine group of TMP (Dias et al., 2014) . However, at the time we were not able to obtain the structure of the closed states of DHFR in complex with these ligands. In order to unveil the differences in the binding mode of these ligands in the two states of MtDHFR, we solved the structures of the MtDHFR-NADPH-PYR and MtDHFR-NADPH-CYC complexes in the closed state to highlight the differences in binding modes.
Superposition of the closed and open states of MtDHFR-NADPH in complex with CYC (r.m.s.d. of 1.05 Å ) indicates that there is not a drastic difference in the position of this ligand [Figs. 6(a)-6(d)]. However, it is possible to observe a displacement in the chlorophenyl ring of about 0.7 Å that adjusts an edge-interaction with Phe31, since there is also a movement of about 0.5 Å between these residues in the structures of the different states. In addition, there is a difference of about 13 in the angle formed between the planes of the chlorobenzyl moieties in the two respective molecules, which probably optimizes a second edge-interaction of CYC in the closed-conformation state of MtDHFR with the nicotinamide moiety of NADPH (not shown). However, we observe a more significantly different binding mode of the PYR molecules in the two states of MtDHFR in comparison to the MtDHFR-NADPH-CYC complexes, although the r.m.s.d. between these two protein chains is also about 1.0 Å . Although the pyrimidine ring has only a small adjustment in its position in relation to the chlorophenyl ring, the angle formed by the planes of the chlorophenyl groups differs by about 50 between the two molecules.
Thermodynamic analysis of antifolates against MtDHFR
In order to determine the dissociation constants (K d ) and thermodynamics of the binding of some antifolates (DIA, MTX and PMX) to MtDHFR, we performed an ITC experiment using the same conditions as reported previously by Dias et al. (2014). However, the titrations of MtDHFR against MTX were performed using CYC as a competitive ligand (Velazquez-Campoy & Freire, 2006) , and despite our efforts to calorimetrically characterize PMX in the presence of MtDHFR, this compound caused protein precipitation inside the calorimeter cell, leading to a large error in the measurements.
Isotherms for the titration of MtDHFR against DIA indicated exothermic behavior at 26 C [ Fig. 7(a) ]. Despite the structural similarities between DIA and TMP, their enthalpies (ÁH) and entropies (TÁS) for binding to MtDHFR are considerably different. The enthalpy varied from À22.8 AE 0.40 kJ mol À1 for DIA to À12.4 AE 0.08 kJ mol À1 for TMP. Similarly, the entropic component changed by approximately threefold for DIA (À9.5 AE 0.8 kJ mol À1 ) compared with TMP (À28.0 AE 0.08 kJ mol À1 ), whereas the Gibbs energies of binding (ÁG) varied modestly for the compounds (À32.3 AE 0.7 and À40.4 AE 0.01 kJ mol À1 , respectively). These variations in ÁH and TÁS might be because of an enthalpy-entropy compensation (EEC), which is a widely observed phenomenon that occurs on the addition of functional groups to the ligand and leads to tighter van der Waals contacts and hydrogen bonds with the protein (giving a more negative ÁH), reducing the translational, rotational and conformational entropy of the protein and/or the ligand (Dragan et al., 2017) .
In this study, we observed conformational changes for MtDHFR and a slightly different binding mode for DIA in the MtDHFR-NADPH-DIA complex compared with the MtDHFR-NADPH-TMP complex (Fig. 6) . These conformational constrictions could contribute to entropic penalties during DIA binding and increase its K d compared with that of TMP (2.2 mM versus 1.4 mM for TMP). However, another reasonable explanation for the EEC could be the number and/or the organization of water molecules trapped in the binding pocket after formation of the MtDHFR-NADPH-DIA complex (Dragan et al., 2017) . Unlike what is observed in the structure of the MtDHFR-NADPH-TMP complex (PDB entry 1dg5; Li et al., 2000) , both protomers in the MtDHFR-NADPH-DIA complex show one or two water molecules sequestered into the hydrophobic pocket of the enzyme ( Supplementary Fig.  S4 ). This phenomenon of solvation has previously been described for other complexes, for example the binding of the GCN4 bZIP to DNA (Dragan et al., 2004) , and could also affect the hydrophobic interactions of DIA with MtDHFR. On the other hand, the presence of an additional methoxy group at the C5 position of the phenyl ring of TMP leads to the removal of the remaining water molecules in the binding pocket, favoring hydrophobic interactions and leading to an entropic contribution (a more negative TÁS; Fig. 7 and Supplementary Fig. S4 ).
In contrast, PYR and CYC are structurally related antifolates with similar thermodynamic profiles for binding to MtDHFR. For both compounds, the driving force of binding seems to be the entropy change (TÁS), indicating a substantial non-electrostatic contribution to these interactions (TÁS = À19.7 AE 0.61 and À24.1 AE 0.20 kJ mol À1 for PYR and CYC, respectively) and leading to Gibbs energies of binding of approximately 34 kJ mol À1 for both compounds [Fig. 7(c) ]. Superposition of the closed structures of MtDHFR-NADPH-PYR and MtDHFR-NADPH-CYC (Dias et al., 2014) did not reveal significant differences in their modes of interaction with the enzyme (r.m.s.d. of 0.09 Å ; Supplementary Table S1 ). These data are correlated with the rigid structures of both compounds, which limits their rotation and consequently minimizes penalties owing to conformational entropy. The observations reported here suggest that increasing the hydrophobic surface that participates in the ligand-protein interaction could be useful for entropic optimization for the design of new antifolates based on the PYR or CYC scaffolds.
Finally, the isotherms for the competitive titration of MTX and MtDHFR in the presence of CYC were exothermic at 26 C [ Fig. 7(b) ]. As expected, the high number of electrostatic interactions in the MtDHFR-NADPH-MTX structure (not shown; Li et al., 2000) is in agreement with the enthalpy-driven profile observed in our thermodynamic analysis of the interaction of this compound and MtDHFR (ÁH = À38.7 AE 0.30 kJ mol À1 and Gibbs energy of binding of À46.2 AE 1.98 kJ mol À1 ) [ Fig. 7(c) ].
Conclusion
In summary, in this work, we have described five crystal structures at high resolution of MtDHFR in ternary complexes with NADPH and different ligands: dihydrofolate and four different antifolates (pyrimethamine, cycloguanil, diaverdine and pemetrexed). Analysis of these structures indicates the binding modes of the different ligands in the active site of MtDHFR and their effects on the structural conformation of MtDHFR. The structure of MtDHFR in complex with NADPH and DHF reveals that, despite a different motion in comparison to EcDHFR, the substrate binds to the active site in the same conformation, while MTX binds with a distinct mode. On the other hand, the different linker in PMX has a significant effect on the conformation of the p-aminobenzoic acid moiety, but there is little influence on the position of the glutamate. In addition, the structure of MtDHFR in complex with NADPH and DIA indicates that the absence of the 5-methoxy group in the dimethoxyphenyl moiety compared with TMP might cause differences in the binding modes of these ligands and in the conformation of the protein structure, and also in the thermodynamic profile. The structures of MtDHFR in complex with NADPH and CYC and PYR in a closed state also have slight changes in the binding mode of these ligands in comparison to the open state, in contrast to the drastic changes observed previously in the binding mode and the conformation of TMP in open and closed states of MtDHFR.
